About
Technology
Issues
FAQ
Links
Official Page
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.